HRP20191013T1 - Protutijela na il-6 i njihova uporaba - Google Patents
Protutijela na il-6 i njihova uporaba Download PDFInfo
- Publication number
- HRP20191013T1 HRP20191013T1 HRP20191013TT HRP20191013T HRP20191013T1 HR P20191013 T1 HRP20191013 T1 HR P20191013T1 HR P20191013T T HRP20191013T T HR P20191013TT HR P20191013 T HRP20191013 T HR P20191013T HR P20191013 T1 HRP20191013 T1 HR P20191013T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- seq
- antibody
- amino acid
- acid sequence
- Prior art date
Links
- 102000004889 Interleukin-6 Human genes 0.000 claims 26
- 108090001005 Interleukin-6 Proteins 0.000 claims 26
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 206010006895 Cachexia Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 206010016256 fatigue Diseases 0.000 claims 10
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 9
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000024908 graft versus host disease Diseases 0.000 claims 7
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 6
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 6
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 5
- 238000002512 chemotherapy Methods 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 208000007502 anemia Diseases 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 3
- 229940039227 diagnostic agent Drugs 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010000234 Abortion spontaneous Diseases 0.000 claims 2
- 206010048998 Acute phase reaction Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000030760 Anaemia of chronic disease Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 201000006082 Chickenpox Diseases 0.000 claims 2
- 208000017667 Chronic Disease Diseases 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- 206010059866 Drug resistance Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000002979 Influenza in Birds Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000027067 Paget disease of bone Diseases 0.000 claims 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000005485 Thrombocytosis Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010046980 Varicella Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000004658 acute-phase response Effects 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000022400 anemia due to chronic disease Diseases 0.000 claims 2
- 206010003230 arteritis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000004988 autoimmune vasculitis Diseases 0.000 claims 2
- 206010064097 avian influenza Diseases 0.000 claims 2
- 208000016738 bone Paget disease Diseases 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 208000013507 chronic prostatitis Diseases 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 238000011503 in vivo imaging Methods 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 208000015994 miscarriage Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 239000012857 radioactive material Substances 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 208000000995 spontaneous abortion Diseases 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010053879 Sepsis syndrome Diseases 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
Claims (13)
1. Anti-IL6 protutijelo obuhvaća:
(a) laki lanac koji obuhvaća (i) varijabilnu laku (VL) domenu koji ima CDR1 polipeptid koji se sastoji od aminokiselinskog slijeda SEQ ID NO:4, CDR2 polipeptida koji se sastoji od aminokiselinskog slijeda SEQ ID NO:5, i CDR3 polipeptida koji se sastoji od aminokiselinskog slijeda SEQ ID NO:6, i (ii) konstantnu laku (CL) domenu koja ima polipeptid koji se sastoji od aminokiselinskog slijeda SEQ ID NO:586; i
(b) teški lanac koji se sastoji od (i) varijabilne teške (VH) domene koja ima CDR1 polipeptid koji se sastoji od aminokiselinskog slijeda SEQ ID NO:7, CDR2 polipeptid koji se sastoji od aminokiselinskog slijeda SEQ ID NO:8 ili SEQ ID NO:120 i CDR3 polipeptid koji se sastoji od aminokiselinskog slijeda SEQ ID NO:9, i (ii) konstantna teška (CH) domena koja sadržava polipeptid koji se sastoji od aminokiselinskog slijeda SEQ ID NO:588,
pri čemu protutijelo ima konstantu disocijacije (KD) manju od 50 pikomola određenu Biacoreom.
2. Anti-IL6 protutijelo sukladno zahtjevu 1,
(a) koje je glikozilirano,
(b) koje je humanizirano protutijelo ili kimerno protutijelo,
(c) koje je humanizirano protutijelo izvedeno iz zečjeg antihumanog IL-6 protutijela,
(d) koje se specifično veže za IL-6 izražen na ljudskim stanicama i/ili za cirkulirajuće topljive molekule IL-6 in vivo,
(e) koje se specifično veže za IL-6 izražen na ili od ljudskih stanica kod pacijenta s bolešću kod koje su razine IL-6 povišene,
pri čemu je bolest odabrana između astme, općeg umora, umora induciranog tjelovježbom, umora povezanog s karcinomom, umora povezanog s upalnom bolesti, sindroma kroničnog umora, kaheksije povezane s karcinomom, kaheksije povezane sa srcem, kaheksije povezane s respiratornim traktom, kaheksije povezane s bubrezima, kaheksije povezane sa starošću, reumatoidnog artritisa, sustavnog eritematoznog lupusa (SLE), sustavnog juvenilnog idiopatskog artritisa, psorijaze, psorijatične artropatije, ankilozantnog spondilitisa, upalne bolesti crijeva (IBD), reumatske polimijalgije, arteritisa velikih stanica, autoimunog vaskulitisa, bolesti presatka protiv primatelja (GVHD), Sjogrenovog sindroma, pojavnosti Stillove bolesti kod odraslih, reumatoidnog artritisa, sustavnog juvenilnog idiopatskog artritisa, osteoartritisa, osteoporoze, Pagetove bolesti kostiju, osteoartritisa, multiplog mijeloma, Hodgkinovog limfoma, non-Hodgkinovog limfoma, karcinoma prostate, leukemije, karcinoma bubrežnih stanica, multicentrične Castelmanove bolesti, karcinoma jajnika, rezistencije na lijekove pri kemoterapiji karcinoma, toksičnosti kemoterapije karcinoma, ishemijske bolesti srca, ateroskleroze, pretilosti, dijabetesa, multiple skleroze, Alzheimerove bolesti, cerebrovaskularne bolesti, vrućice, odgovora akutne faze, alergija, anemije, anemije koja prati upalu (anemije kronične bolesti), hipertenzije, depresije, depresije povezane s kroničnom bolešću, tromboze, trombocitoze, akutnog zatajenja srca, metaboličkog sindroma, pobačaja, pretilosti, kroničnog prostatitisa, glomerulonefritisa, upalne bolesti u zdjelici, reperfuzijske ozljede, odbacivanja transplantata, bolesti presatka protiv primatelja (GVHD), ptičje gripe, vodenih kozica, pandemijske gripe, respiratornog distres sindroma kod odraslih (ARDS), ozbiljnog akutnog respiratornog sindroma (SARS), sepse, sindroma sustavnog upalnog odgovora (SIRS), karcinomakarcinoma, upalnog poremećaja, virusnog poremećaja, ili autoimunog poremećaja, artritisa, kaheksije, i sindroma umora,
(f) koje je izravno ili neizravno povezano s odvojivim obilježivačem ili terapijskim agensom,
(g) koje se veže za najmanje jedan topljivi IL-6, na staničnoj površini izraženi IL-6, IL-6/IL-6R, IL-6/IL-6R/gp130 komplekse i/ili multimere IL-6/IL-6R/gp130 kompleksa,
(h) koje antagonizira biološke učinke jednog ili više od topljivog IL-6, na površini stanice izraženog IL-6, IL-6/IL-6R, IL-6/IL-6R/gp130 kompleksa i/ili multimera IL-6/IL-6R/gp130 kompleksa,
(i) pri čemu VH ili VL polipeptidi sadržani u navedenom protutijelu potječu iz jedne ili više populacija zečjih B stanica,
(j) koje nema specifičnost vezanja za topljivi IL-6R (sIL-6R) ili gp130,
(k) koje inhibira povezivanje IL-6 s IL-6R i/ili stvaranje IL-6/IL-6R/gp130 kompleksa i/ili stvaranje IL-6/IL-6R/gp130 multimera, ili
(l) koje nadalje nadalje obuhvaća efektorski dio odabran između:
(i) odvojivog dijela odabranog između fluorescentne boje, enzima, supstrata, bioluminescentnog materijala, radioaktivnog materijala, i kemiluminescentnog materijala, i
(ii) funkcijskog dijela odabranog između streptavidina, avidina, biotina, citotoksina, citotoksičnog agensa, radioaktivnog materijala.
3. Anti-IL-6 protutijelo sukladno patentnom zahtjevu 1, sadrži VL lanac i VH lanac, redom, koji obuhvaćaju aminokiselinske sljedove SEQ ID NO:2 i SEQ ID NO:3; SEQ ID NO:2 i SEQ ID NO:18; SEQ ID NO:2 i SEQ ID NO:19; SEQ ID NO:20 i SEQ ID NO:3; SEQ ID NO:20 i SEQ ID NO:18; ili SEQ ID NO:20 i SEQ ID NO:19, ili protutijelo sadrži VL lanac i VH lanac, redom, koji ima aminokiselinske sljedove koji k tome imaju najmanje 90% ili više homologije.
4. Slijed nukleinskih kiselina koji kodira anti-IL-6 protutijelo sukladno bilo kojem od patentnih zahtjeva 1-3.
5. Vektor koji sadrži slijed nukleinske kiseline sukladno patentnom zahtjevu 4.
6. Rekombinantna stanica koja izražava anti-IL-6 protutijelo sukladno bilo kojem od patentnih zahtjeva 1-3.
7. Farmaceutski ili dijagnostički sastav koji sadrži najmanje jedno anti-IL-6 protutijelo sukladno bilo kojem od patentnih zahtjeva 1-3 i farmaceutski prihvatljivi nosač.
8. Farmaceutski ili dijagnostički sastav iz patentnog zahtjeva 7,
a) koji nadalje sadrži najmanje jedan stabilizator,
b) koji je liofiliziran, ili
c) koji sadrži jedno ili više anti-IL-6 protutijela koja sadrže (a) VH lanac koji ima aminokiselinski slijed SEQ ID NO:3, 18 ili 19; i (b) VL lanac koji ima aminokiselinski slijed SEQ ID NO:2 ili 20.
9. Anti-IL-6 protutijelo sukladno bilo kojem od patentnih zahtjeva 1-3 za uporabu kao terapijski ili dijagnostički agens.
10. Uporaba anti-IL-6 protutijela sukladno bilo kojem od patentnih zahtjeva 1-3 u proizvodnji lijeka ili u proizvodnji agensa za uporabu u metodi liječenja.
11. Anti-IL-6 protutijelo za uporabu kao terapijski agens sukladno patentnom zahtjevu9 ili sukladno patentnom zahtjevu 10:
a) pri čemu je bolest odabrana između astme, općeg umora, umora induciranog tjelovježbom, umora uslijed karcinoma, umora povezanog s upalnom bolesti, sindroma kroničnog umora, kaheksije povezane s karcinomom, kaheksije povezane sa srcem, kaheksije respiratornog trakta, kaheksije povezane s bubrezima, kaheksije povezane sa starošću, reumatoidnog artritisa, sustavnog eritematoznog lupusa (SLE), sustavnog juvenilnog idiopatskog artritisa, psorijaze, psorijatične artropatije, ankilozantnog spondilitisa, upalne bolesti crijeva (IBD), reumatske polimijalgije, arteritisa velikih stanica, autoimunog vaskulitisa, bolesti presatka protiv primatelja (GVHD), Sjogrenovog sindroma, pojavnosti Stillove bolesti kod odraslih, reumatoidnog artritisa, sustavnog juvenilnog idiopatskog artritisa, osteoartritisa, osteoporoze, Pagetove bolesti kostiju, osteoartritisa, multiplog mijeloma, Hodgkinovog limfoma, non-Hodgkinovog limfoma, karcinoma prostate, leukemije, karcinoma bubrežnih stanica, multicentrične Castelmanove bolesti, karcinoma jajnika, rezistencije na lijekove pri kemoterapiji karcinoma, toksičnosti kemoterapije karcinoma, ishemijske bolesti srca, ateroskleroze, pretilosti, dijabetesa, multiple skleroze, Alzheimerove bolesti, cerebrovaskularne bolesti, vrućice, odgovora akutne faze, alergija, anemije, anemije koja prati upalu (anemije kronične bolesti), hipertenzije, depresije, depresije povezane s kroničnom bolešću, tromboze, trombocitoze, akutnog zatajenja srca, metaboličkog sindroma, pobačaja, kroničnog prostatitisa, glomerulonefritisa, upalne bolesti u zdjelici, reperfuzijske ozljede, odbacivanja transplantata, bolesti presatka protiv primatelja (GVHD), ptičje gripe, vodenih kozica, pandemijske gripe, respiratornog distres sindroma kod odraslih (ARDS), ozbiljnog akutnog respiratornog sindroma (SARS), sepse, i sindroma sustavnog upalnog odgovora (SIRS), artritisa, karcinoma, autoimune bolesti, ili upalnog stanja,
b) pri čemu liječenje nadalje uključuje davanje drugog terapijskog agensa ili režima odabranog između kemoterapije, radioterapije, davanja citokina, ili genske terapije, ili
c) koje se koristi za liječenje nuspojava karcinoma ili virusne infekcije, preferabilno kod koje je nuspojava umor ili gubitak tjelesne mase.
12. Anti-IL-6 protutijelo za uporabu kao dijagnostički agens sukladno patentnom zahtjevu 9, pri čemu je uporaba za dijagnostičke in vivo slikovne tehnike
a) pri čemu navedena uporaba koja otkriva prisutnost stanica koje eksprimiraju IL-6 obuhvaća davanje dijagnostički učinkovite količine najmanje jednog anti-humanog IL-6 protutijela sukladno patentnom zahtjevu 1,
b) pri čemu navedena primjena nadalje uključuje davanje radionuklida ili fluorofora koji pospješuje detekciju protutijela na IL-6 ekspresijskim mjestima bolesti,
c) koje se koristi za prepoznavanje tumora ili metastaza koji eksprimiraju IL-6,
d) koje se koristi za prepoznavanje mjesta upale povezanih sa stanicama koje izražavaju IL-6, ili
e) pri čemu se rezultati koriste za poboljšanje dizajna odgovarajućeg terapijskog režima.
13. Anti-IL-6 protutijelo za uporabu kao dijagnostički agens sukladno patentnom zahtjevu 9, pri čemu je uporaba za dijagnostičke in vivo slikovne tehnike
a) za detekciju ili prikazivanje tumora ili metastaza koji izražavaju IL-6, ili
b) za detekciju ili prikazivanje upalnih mjesta koja izražavaju IL-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92455007P | 2007-05-21 | 2007-05-21 | |
| EP16195797.2A EP3187506B1 (en) | 2007-05-21 | 2008-05-21 | Antibodies to il-6 and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191013T1 true HRP20191013T1 (hr) | 2019-08-23 |
Family
ID=40122295
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170038TT HRP20170038T1 (hr) | 2007-05-21 | 2017-01-10 | Protutijela na il-6 i njihova uporaba |
| HRP20191013TT HRP20191013T1 (hr) | 2007-05-21 | 2019-06-04 | Protutijela na il-6 i njihova uporaba |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170038TT HRP20170038T1 (hr) | 2007-05-21 | 2017-01-10 | Protutijela na il-6 i njihova uporaba |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US7935340B2 (hr) |
| EP (2) | EP2164514B1 (hr) |
| JP (4) | JP5833823B2 (hr) |
| KR (3) | KR101741731B1 (hr) |
| CN (2) | CN105001332B (hr) |
| AU (1) | AU2008254584B2 (hr) |
| BR (1) | BRPI0811782A2 (hr) |
| CA (2) | CA2688146C (hr) |
| CO (1) | CO6241159A2 (hr) |
| CY (2) | CY1119068T1 (hr) |
| DK (2) | DK3187506T3 (hr) |
| EA (1) | EA200901533A1 (hr) |
| ES (2) | ES2610607T3 (hr) |
| HK (1) | HK1138796A1 (hr) |
| HR (2) | HRP20170038T1 (hr) |
| HU (2) | HUE043782T2 (hr) |
| IL (4) | IL202238A (hr) |
| LT (2) | LT3187506T (hr) |
| MX (2) | MX349322B (hr) |
| NO (2) | NO344119B1 (hr) |
| NZ (2) | NZ597767A (hr) |
| PL (2) | PL3187506T3 (hr) |
| PT (2) | PT3187506T (hr) |
| SG (1) | SG183742A1 (hr) |
| SI (2) | SI2164514T1 (hr) |
| TR (1) | TR201905366T4 (hr) |
| TW (2) | TWI561530B (hr) |
| WO (1) | WO2008144763A2 (hr) |
| ZA (1) | ZA200908770B (hr) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2450830C2 (ru) | 2005-10-21 | 2012-05-20 | Чугаи Сейяку Кабусики Кайся | Средства для лечения кардиопатии |
| JP5754875B2 (ja) | 2006-04-07 | 2015-07-29 | 国立大学法人大阪大学 | 筋再生促進剤 |
| ES2564392T3 (es) * | 2007-01-23 | 2016-03-22 | Shinshu University | Inhibidores de IL-6 para el tratamiento de rechazo crónico |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| NZ597767A (en) * | 2007-05-21 | 2013-06-28 | Bristol Myers Squibb Co | Antibodies to IL-6 and use thereof |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US20150050288A1 (en) * | 2007-09-06 | 2015-02-19 | The Johns Hopkins University | Treatment of TH17-Mediated Autoimmune Disease Via Inhibition of Stat3 |
| EP2959917A3 (en) | 2007-10-19 | 2016-02-24 | The Regents of The University of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| US8277804B2 (en) | 2008-05-21 | 2012-10-02 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| WO2009148148A1 (ja) | 2008-06-05 | 2009-12-10 | 国立がんセンター総長が代表する日本国 | 神経浸潤抑制剤 |
| US8188235B2 (en) * | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| AU2016250477B2 (en) * | 2008-11-25 | 2018-07-05 | Vitaeris Inc. | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| MX2011005408A (es) * | 2008-11-25 | 2011-06-16 | Alder Biopharmaceuticals Inc | Antagonistas de il-6 para prevenir o tratar la trombosis. |
| AU2013203804B2 (en) * | 2008-11-25 | 2016-10-13 | Vitaeris Inc. | Antibodies to il-6 and use thereof |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| WO2010071610A1 (en) * | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
| SG10201704214VA (en) * | 2009-01-29 | 2017-06-29 | Medimmune Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| SI2493922T1 (sl) | 2009-10-26 | 2017-06-30 | F. Hoffmann-La Roche Ag | Postopek za proizvodnjo glikoziliranega imunoglobulina |
| KR20120118088A (ko) | 2009-11-24 | 2012-10-25 | 앨더바이오 홀딩스 엘엘씨 | Ⅰｌ-6에 대한 항체 및 이들의 용도 |
| AU2016250478A1 (en) * | 2009-11-24 | 2016-11-17 | Alder Biopharmaceuticals, Inc. | Antibodies to IL-6 and use thereof |
| US9775921B2 (en) * | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| PL2400298T3 (pl) | 2010-05-28 | 2014-01-31 | Hoffmann La Roche | Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał |
| SI2578231T1 (sl) | 2010-05-28 | 2023-01-31 | Chugai Seiyaku Kabushiki Kaisha | Okrepljen protitumorski T celični odzivnik |
| WO2012071561A2 (en) | 2010-11-23 | 2012-05-31 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of anemia |
| WO2012075340A2 (en) | 2010-12-01 | 2012-06-07 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| ES2657970T3 (es) * | 2010-12-01 | 2018-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos contra ROR1 de conejo/ser humano quiméricos |
| US8597883B2 (en) | 2011-02-14 | 2013-12-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biomarkers for cancer-related fatigue and use thereof |
| JP6374789B2 (ja) | 2011-05-20 | 2018-08-15 | アルダーバイオ・ホールディングズ・エルエルシー | 羞明または光嫌悪症を予防または抑制する抗ｃｇｒｐ抗体および抗体断片のそれを必要とする対象、特に片頭痛患者における使用 |
| PT3495392T (pt) | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| US9855332B2 (en) | 2011-05-20 | 2018-01-02 | Alderbio Holdings Llc | Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels |
| WO2012161956A2 (en) | 2011-05-20 | 2012-11-29 | Alder Biopharmaceuticals, Inc. | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as pichia pastoris |
| KR101978534B1 (ko) * | 2011-08-19 | 2019-08-28 | 앨더바이오 홀딩스 엘엘씨 | 변형된 미생물 이를 테면 피치아 파스토리스(pichia pastoris)에서 다수의 아단위 단백질들, 이를 테면 항체의 고역가 및 고순도 생산을 위한 다중-복사체 전략 |
| US10150968B2 (en) | 2011-08-19 | 2018-12-11 | Alderbio Holdings Llc | Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| EP2583980A1 (en) * | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| BR112014010455A2 (pt) | 2011-11-23 | 2018-08-07 | Hoffmann La Roche | Métodos para produzir um anticorpo, usos de il-e2 e/ou il-21, métodos para cultivar uma célula, usos de uma célula de mamífero e uso de sac no co- cultivo de células b |
| EP2794652B1 (en) | 2011-12-21 | 2017-11-15 | F. Hoffmann-La Roche AG | Rapid method for cloning and expression of cognate antibody variable region gene segments |
| WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
| HUE048947T2 (hu) | 2012-07-13 | 2020-09-28 | Univ Pennsylvania | CAR-ok tumorellenes hatásának toxicitás-menedzsmentje |
| AU2013342163B2 (en) * | 2012-11-08 | 2018-08-16 | F. Hoffmann-La Roche Ltd | IL-6 antagonists and uses thereof |
| US9062104B2 (en) | 2013-03-14 | 2015-06-23 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
| EP2971037B1 (en) | 2013-03-15 | 2019-07-10 | Alder Biopharmaceuticals, Inc. | Temperature shift for high yield expression of polypeptides in yeast and other transformed cells |
| EP3754012A1 (en) | 2013-03-15 | 2020-12-23 | Alder Biopharmaceuticals, Inc. | Antibody purification and purity monitoring |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| WO2015003122A2 (en) | 2013-07-03 | 2015-01-08 | Alder Biopharmaceuticals, Inc. | Regulation of glucose metabolism using anti-cgrp antibodies |
| CN105198982B (zh) * | 2014-06-18 | 2019-07-26 | 上海交通大学 | 基于il-6的抗原表位及其应用 |
| IL251858B (en) * | 2014-11-07 | 2022-09-01 | Eleven Biotherapeutics Inc | Improved il–6 antagonists |
| IL284291B1 (en) | 2014-12-19 | 2024-10-01 | Lundbeck Seattle Biopharmaceuticals Inc | Human anti-ACTH antibodies and their use |
| DE102016002298A1 (de) | 2015-03-06 | 2016-09-08 | Shimano Inc. | Elektrischer Fahrradhinterumwerfer |
| US10029754B2 (en) | 2015-03-06 | 2018-07-24 | Shimano Inc. | Bicycle electrical system |
| DE102016001333A1 (de) | 2015-03-06 | 2016-09-08 | Shimano Inc. | Elektrische fahrradkomponentenanordnung |
| TWI810073B (zh) | 2015-03-06 | 2023-07-21 | 日商島野股份有限公司 | 自行車電組件 |
| WO2016160923A1 (en) * | 2015-03-31 | 2016-10-06 | Janssen Biotech, Inc | Antigen binding proteins |
| EP3305325A4 (en) | 2015-06-04 | 2019-01-16 | National Center of Neurology and Psychiatry | ACTIVE AGENT FOR THE THERAPY OF MENTAL ILLNESSES WITH IL-6 INHIBITOR AS AN ACTIVE AGENT |
| EP3419599A4 (en) | 2016-02-23 | 2019-09-11 | Sesen Bio, Inc. | IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF |
| ES2951698T3 (es) | 2016-03-30 | 2023-10-24 | Hoffmann La Roche | Procedimiento de cultivo de linfocitos B |
| CA3020990A1 (en) | 2016-04-15 | 2017-10-19 | Alder Biopharmaceuticals, Inc. | Humanized anti-pacap antibodies and uses thereof |
| TWI787594B (zh) | 2016-07-12 | 2022-12-21 | 美商凱特製藥公司 | 抗原結合分子和使用彼之方法 |
| EP3562936B1 (en) | 2017-01-02 | 2024-05-22 | F. Hoffmann-La Roche AG | B-cell cultivation method |
| SG11201906852XA (en) | 2017-02-01 | 2019-08-27 | Univ Yale | Treatment of diuretic resistance |
| KR102616335B1 (ko) | 2017-02-28 | 2023-12-21 | 브이아이비 브이지더블유 | 경구 단백질 전달을 위한 수단 및 방법 |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| EP3625332B1 (en) | 2017-05-19 | 2022-02-02 | F. Hoffmann-La Roche AG | Method for the production of thymocyte supernatant |
| EP3634477A4 (en) * | 2017-06-06 | 2021-03-03 | The Regents of the University of California | IMMUNOASSAY FOR HUMANESE ERYTHROFERRON |
| US20200369774A1 (en) * | 2017-09-13 | 2020-11-26 | Jiangsu Hengrui Medicine Co., Ltd. | Il-6r antibody and antigen binding fragment thereof and medical use |
| US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
| JP7166342B2 (ja) | 2017-11-30 | 2022-11-07 | エフ．ホフマン－ラ ロシュ アーゲー | Ｂ細胞培養法 |
| CN111867627A (zh) * | 2018-01-04 | 2020-10-30 | 维塔里斯股份有限公司 | 抗IL-6抗体例如克拉扎珠单抗(Clazakizumab)用于使实体器官移植接受者脱敏和/或用于预防、稳定或减轻抗体介导的排斥(ABMR)的用途 |
| EA202091640A1 (ru) | 2018-01-05 | 2020-10-26 | Корвидиа Терапьютикс, Инк. | Способы лечения опосредованного il-6 воспаления без иммунодепрессии |
| WO2020006469A1 (en) * | 2018-06-29 | 2020-01-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating and reducing traumatic brain injury-associated impairments using sgp130 |
| EP3847192A4 (en) * | 2018-09-05 | 2022-09-21 | The Board Of Regents Of The University Of Texas System | MONOCLONAL ANTIBODIES ANTI-ENDOTROPHIN AND THEIR USE |
| CN109517064B (zh) * | 2018-10-10 | 2020-05-08 | 北京汇智和源生物技术有限公司 | 白介素-6的人源化单克隆抗体、其编码基因及应用 |
| EP3877412A4 (en) | 2018-11-08 | 2022-08-10 | Cedars-Sinai Medical Center | USE OF CLAZAKIZUMAB TO DESENSITIZE AND IMPROVE KIDNEY TRANSPLANTATION IN HLA-SENSITIZED PATIENTS |
| CN113194996B (zh) * | 2018-12-20 | 2024-06-28 | 西达赛奈医疗中心 | 克拉扎珠单抗用于治疗慢性抗体介导的器官移植物排斥反应 |
| PE20211707A1 (es) | 2019-01-08 | 2021-09-01 | H Lundbeck As | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp |
| CN114144436A (zh) | 2019-07-24 | 2022-03-04 | H.隆德贝克有限公司 | 抗mGluR5抗体及其用途 |
| US20230078330A1 (en) * | 2020-01-27 | 2023-03-16 | Vanderbilt University | Human anti-dengue antibodies and methods of use therefor |
| CN111228480A (zh) * | 2020-02-24 | 2020-06-05 | 浙江正熙生物医药有限公司 | 抗人TNF-α抗体在制备用于治疗病毒感染的药物中的应用 |
| SG10202003296VA (en) | 2020-04-06 | 2021-11-29 | H Lundbeck As | Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies |
| WO2022054565A1 (ja) | 2020-09-08 | 2022-03-17 | デクソンファーマシューティカルズ株式会社 | サイトカインストーム抑制剤、サイトカインストーム抑制剤の使用方法およびスクリーニング方法 |
| JP2024508222A (ja) * | 2021-01-29 | 2024-02-26 | アムジエン・インコーポレーテツド | 抗Ｍｃｌ１抗体を投与することによる癌を監視するための材料及び方法 |
| JP6974892B1 (ja) | 2021-05-27 | 2021-12-01 | デクソンファーマシューティカルズ株式会社 | 癌悪液質の改善剤および癌悪液質の改善方法 |
| WO2023026245A1 (en) | 2021-08-27 | 2023-03-02 | H. Lundbeck A/S | Treatment of cluster headache using anti-cgrp antibodies |
| CN115819578B (zh) * | 2022-10-29 | 2023-08-18 | 武汉爱博泰克生物科技有限公司 | 高亲和力Human IL-5兔单克隆抗体及其应用 |
| CN116715763B (zh) * | 2022-11-22 | 2023-11-24 | 武汉爱博泰克生物科技有限公司 | Mouse IL-6兔单克隆抗体对及其制备方法和应用 |
| CN117797317A (zh) * | 2024-02-29 | 2024-04-02 | 四川大学 | 一种肽微球-壳聚糖复合材料的制备方法及其产品和应用 |
| CN118515763B (zh) * | 2024-07-23 | 2024-11-01 | 北京百普赛斯生物科技股份有限公司 | Il-6的抗体、检测试剂盒及其应用 |
Family Cites Families (167)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL58765A (en) * | 1979-11-21 | 1986-09-30 | Yeda Res & Dev | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
| US5554513A (en) | 1979-11-21 | 1996-09-10 | Yeda Research & Development Co. Ltd. | Production of recombinant human interferon-beta2 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| IL88375A (en) * | 1988-11-14 | 1995-07-31 | Yeda Res & Dev | Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5216128A (en) * | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
| DE10399036I1 (de) | 1989-08-07 | 2004-04-01 | Peptide Technology Ltd | Bindeligande für Tumornekrosisfaktor. |
| US5202422A (en) | 1989-10-27 | 1993-04-13 | The Scripps Research Institute | Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0542810A1 (en) * | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| CA2056102C (en) | 1990-11-26 | 2003-03-25 | Petrus Gerardus Antonius Steenbakkers | Method for the production of antibodies |
| AU1643692A (en) * | 1991-03-07 | 1992-10-06 | Seragen, Inc. | Use of cell surface receptor targeted molecules for the treatment of viral diseases |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| TW205553B (hr) | 1991-04-25 | 1993-05-11 | Chugai Pharmaceutical Co Ltd | |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| JPH05304986A (ja) * | 1992-04-28 | 1993-11-19 | Tosoh Corp | ｇｐ１３０蛋白質に対するモノクロ−ナル抗体 |
| WO1994004659A1 (en) * | 1992-08-21 | 1994-03-03 | United States Of America, As Represented By The Secretary, Department Of Health & Human Services | A novel b-lymphoma cell line and antigen |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| WO1994021293A1 (en) | 1993-03-19 | 1994-09-29 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| TW458985B (en) | 1993-05-31 | 2001-10-11 | Chugai Pharmaceutical Co Ltd | Reconstructed human antibody against human interleukin-6 |
| US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| FR2707882B1 (fr) * | 1993-07-23 | 1997-08-01 | Immunotech Sa | Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant. |
| NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| US5882872A (en) | 1994-04-28 | 1999-03-16 | Kudsk; Kenneth A. | Use of an IL-6 assay for predicting the development of post-trauma complications |
| US5646005A (en) * | 1994-04-28 | 1997-07-08 | Kudsk; Kenneth A. | Use of an IL-6 assay for predicting the development of post-trauma complications |
| US5707624A (en) | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
| US6083501A (en) | 1994-06-07 | 2000-07-04 | Toray Industries, Inc. | Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases |
| US5545623A (en) | 1994-06-10 | 1996-08-13 | Akira Matsumori | Method of inhibiting secretion of inflammatory cytokines |
| US8017121B2 (en) * | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| PL182089B1 (en) | 1994-10-21 | 2001-11-30 | Chugai Pharmaceutical Co Ltd | Pharmaceutic compositions for treating diseases caused by production of il-6 |
| WO1996020728A1 (fr) * | 1994-12-29 | 1996-07-11 | Chugai Seiyaku Kabushiki Kaisha | Potentialisateur d'agent antitumoral comprenant un antagoniste de l'interleukine 6 |
| US6261560B1 (en) * | 1995-02-13 | 2001-07-17 | Chugai Seiyaku Kabushiki Kaisha | Method for inhibiting muscle protein proteolysis with antibodies to interleukin-6 receptor |
| US6482927B1 (en) * | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| AU2160297A (en) * | 1996-03-30 | 1997-10-22 | Boehringer Mannheim Gmbh | Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors |
| US5854398A (en) * | 1996-07-25 | 1998-12-29 | The Trustees Of Columbia University In The City Of New York | Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof |
| DK0826696T3 (da) * | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| EP2322216A1 (en) * | 1997-03-21 | 2011-05-18 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| PL193575B1 (pl) | 1997-05-15 | 2007-02-28 | Chugai Pharmaceutical Co Ltd | Zastosowanie przeciwciała przeciwko białku pokrewnemu z hormonem przytarczyc (PTHrP) |
| DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| US6407218B1 (en) | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
| ES2333071T5 (es) * | 1998-01-14 | 2015-08-17 | Novartis Vaccines And Diagnostics S.R.L. | Antígenos de Neisseria meningitidis |
| PT1074268E (pt) | 1998-03-17 | 2008-02-28 | Chugai Pharmaceutical Co Ltd | Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6 |
| CA2327505A1 (en) * | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
| GB9815909D0 (en) * | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
| US6838290B2 (en) | 1998-08-21 | 2005-01-04 | Immunex Corporation | Methods for screening compounds that affect IL-1 epsilon activity |
| US7345217B2 (en) | 1998-09-22 | 2008-03-18 | Mendel Biotechnology, Inc. | Polynucleotides and polypeptides in plants |
| ATE255420T1 (de) | 1998-09-25 | 2003-12-15 | Horst Lindhofer | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung |
| ATE422205T1 (de) * | 1998-10-21 | 2009-02-15 | Chugai Pharmaceutical Co Ltd | Verfahren zum screenen von verbindungen, die die produktion von entzündungszytokinen inhibieren |
| US6972125B2 (en) * | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| US6419944B2 (en) * | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| US6342587B1 (en) * | 1999-10-22 | 2002-01-29 | Ludwig Institute For Cancer Research | A33 antigen specific immunoglobulin products and uses thereof |
| US7094566B2 (en) | 2000-03-16 | 2006-08-22 | Amgen Inc., | IL-17 receptor like molecules and uses thereof |
| US6939547B2 (en) | 2000-07-31 | 2005-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Specific binding agents for KSHV vIL-6 that neutralize a biological activity |
| KR100870123B1 (ko) | 2000-10-20 | 2008-11-25 | 츄가이 세이야꾸 가부시키가이샤 | 저분자화 아고니스트 항체 |
| ATE387215T1 (de) | 2000-10-25 | 2008-03-15 | Chugai Pharmaceutical Co Ltd | Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff |
| WO2002036164A1 (fr) | 2000-10-27 | 2002-05-10 | Chugai Seiyaku Kabushiki Kaisha | Agent abaissant le taux sanguin de vegf contenant un antagoniste de il-6 en tant que principe actif |
| AU2000279625A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient |
| IL139380A0 (en) * | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
| US20040198661A1 (en) | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7462694B2 (en) * | 2001-02-02 | 2008-12-09 | Rutgers, The State University | C-terminally truncated non-cytotoxic PAP mutants |
| US7169573B2 (en) | 2001-02-20 | 2007-01-30 | Oklahoma Medical Research Foundation | Method for monitoring coagulability and hypercoagulable states |
| UA80091C2 (en) * | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| JP2003066047A (ja) | 2001-06-14 | 2003-03-05 | Matsushita Electric Ind Co Ltd | 免疫反応測定方法及びそれに用いる免疫反応測定用試薬 |
| IL159771A0 (en) * | 2001-07-09 | 2004-06-20 | Combinatorx Inc | Combinations for the treatment of inflammatory disorders |
| US20030219839A1 (en) * | 2001-09-20 | 2003-11-27 | Katherine Bowdish | Anti-PDGF antibodies and methods for producing engineered antibodies |
| ES2624547T3 (es) * | 2001-11-14 | 2017-07-14 | Janssen Biotech, Inc. | Anticuerpos anti il 6, composiciones, métodos y usos |
| US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
| AU2002357759A1 (en) * | 2001-11-21 | 2003-06-10 | Mark W. Appelby | Manipulation of cytokine levels using cd83 gene products |
| US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| GB0209884D0 (en) | 2002-04-30 | 2002-06-05 | Ares Trading Sa | Proteins |
| US20030229030A1 (en) * | 2002-06-11 | 2003-12-11 | Theoharides Theoharis C. | Method of treating interleukin-6-mediated inflammatory diseases |
| EP1519958B1 (en) | 2002-06-14 | 2014-10-15 | Immunomedics, Inc. | Humanized monoclonal antibody hpam4 |
| WO2004003544A1 (en) | 2002-06-26 | 2004-01-08 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders |
| CA2492524A1 (en) * | 2002-08-15 | 2004-02-26 | Epitomics, Inc. | Humanized rabbit antibodies |
| US20060275294A1 (en) * | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078532A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060078533A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US7482436B2 (en) | 2002-08-30 | 2009-01-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of antibody |
| CN101972478B (zh) | 2002-10-08 | 2012-10-31 | 免疫医疗公司 | 抗体治疗 |
| EP1572976B1 (en) * | 2002-11-21 | 2010-09-15 | Celltech R & D, Inc. | Modulating immune responses |
| RU2377253C2 (ru) * | 2002-12-02 | 2009-12-27 | Амген Фремонт,Инк. | Антитела, специфичные к фактору некроза опухолей, и их применение |
| US20060281130A1 (en) | 2002-12-20 | 2006-12-14 | Elisabeth Bock | Metod of modulation of interaction between receptor and ligand |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| CN101130077A (zh) | 2003-02-24 | 2008-02-27 | 中外制药株式会社 | 含有白介素6拮抗剂的脊髓损伤治疗剂 |
| GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| ES2527102T3 (es) * | 2003-06-19 | 2015-01-20 | Genentech, Inc. | Composiciones y métodos para el tratamiento de trastornos relacionados con la coagulación |
| US20050048578A1 (en) | 2003-06-26 | 2005-03-03 | Epitomics, Inc. | Methods of screening for monoclonal antibodies with desirable activity |
| US20060210563A1 (en) | 2003-07-25 | 2006-09-21 | Juan Lopez De Silanes | Administration of anti-cytokine f(ab')2 antibody fragments |
| US20050033031A1 (en) * | 2003-08-07 | 2005-02-10 | Couto Fernando Jose Rebelo Do | Methods for humanizing rabbit monoclonal antibodies |
| WO2005037314A1 (en) * | 2003-08-20 | 2005-04-28 | Centocor, Inc. | Method for generating antibodies |
| JP2007503206A (ja) * | 2003-08-22 | 2007-02-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法 |
| CA2536675A1 (en) * | 2003-08-29 | 2005-03-10 | Centocor, Inc. | A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method |
| US7634360B2 (en) | 2003-09-23 | 2009-12-15 | Prediction Sciences, LL | Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof |
| US7392140B2 (en) | 2003-09-23 | 2008-06-24 | Prediction Sciences, Llc | Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof |
| MXPA06003768A (es) | 2003-10-17 | 2006-06-23 | Chugai Pharmaceutical Co Ltd | Agente terapeutico para el mesotelioma. |
| HUE033349T2 (en) | 2003-10-22 | 2017-11-28 | Keck Graduate Inst | Procedures for the Synthesis of Heteromultimer Polypeptides in Yeast Using an Hagloid Mating Strategy |
| US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
| MXPA06014023A (es) * | 2004-06-29 | 2007-02-08 | Warner Lambert Co | Terapias combinadas que utilizan inhibidores de benzamida del receptor p2x7. |
| US7727528B2 (en) * | 2004-07-22 | 2010-06-01 | Early Detection, Llc | Methods for diagnosis using anti-cytokine receptor antibodies |
| US20060051348A1 (en) * | 2004-09-09 | 2006-03-09 | Jorn Gorlach | Method of producing a plurality of isolated antibodies to a plurality of cognate antigens |
| US20070036788A1 (en) | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
| US20060121042A1 (en) * | 2004-10-27 | 2006-06-08 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US20060171943A1 (en) | 2005-02-01 | 2006-08-03 | Amgen Inc. | Compositions and methods of treating fibrotic disorders |
| ITRM20050103A1 (it) | 2005-03-10 | 2006-09-11 | Rocco Savino | Associazione di antagonisti della interleuchina 6 e farmaci antiproliferativi. |
| US20080033027A1 (en) | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
| US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| PE20061324A1 (es) * | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
| WO2007027805A2 (en) | 2005-08-30 | 2007-03-08 | Centocor, Inc. | Method for generating anti-variable region monoclonal antibodies |
| EP1991270A4 (en) | 2005-12-22 | 2009-12-02 | Anaborex Inc | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CACHEXIA |
| ES2382164T3 (es) | 2005-12-30 | 2012-06-05 | Merck Patent Gmbh | Anticuerpos anti-IL-6 que impiden la unión de la IL-6 en complejo con el IL-6R( ) a la GP130 |
| US7790463B2 (en) | 2006-02-02 | 2010-09-07 | Yale University | Methods of determining whether a pregnant woman is at risk of developing preeclampsia |
| JP2009529339A (ja) * | 2006-03-13 | 2009-08-20 | アブリンクス エン．ヴェー． | Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド |
| US7504106B2 (en) | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
| EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
| CN101600793B (zh) | 2006-05-19 | 2013-06-26 | 奥尔德生物制药公司 | 用于获得抗原特异性b细胞的克隆群体的培养方法 |
| WO2007139359A1 (en) | 2006-05-31 | 2007-12-06 | Hanwha Chemical Corporation | Vcam-1 specific monoclonal antibody |
| EP2041177B1 (en) | 2006-06-02 | 2011-12-14 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| MX2009001110A (es) | 2006-08-03 | 2009-05-11 | Vaccinex Inc | Anticuerpos monoclonales anti-il-6 y usos de los mismos. |
| CN101512008B (zh) * | 2006-09-08 | 2015-04-01 | 艾伯维巴哈马有限公司 | 白介素-13结合蛋白 |
| US20080081041A1 (en) * | 2006-09-29 | 2008-04-03 | Jeffrey Nemeth | Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer |
| AU2007317333A1 (en) | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| ES2564392T3 (es) | 2007-01-23 | 2016-03-22 | Shinshu University | Inhibidores de IL-6 para el tratamiento de rechazo crónico |
| EP2162469A4 (en) | 2007-05-21 | 2012-08-01 | Alderbio Holdings Llc | NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US20090238825A1 (en) | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8252286B2 (en) * | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| NZ597767A (en) * | 2007-05-21 | 2013-06-28 | Bristol Myers Squibb Co | Antibodies to IL-6 and use thereof |
| US9585899B2 (en) * | 2007-06-19 | 2017-03-07 | The Johns Hopkins University | Method of inhibiting platelet aggregation and clot formation |
| US8277804B2 (en) | 2008-05-21 | 2012-10-02 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| EP2349331A4 (en) * | 2008-11-13 | 2012-12-12 | Femta Pharmaceuticals Inc | HUMANIZED ANTIBODIES TO IL-6 |
| US10227404B2 (en) | 2008-11-25 | 2019-03-12 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US9212223B2 (en) * | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8323649B2 (en) * | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| MX2011005408A (es) | 2008-11-25 | 2011-06-16 | Alder Biopharmaceuticals Inc | Antagonistas de il-6 para prevenir o tratar la trombosis. |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| CA2765220A1 (en) | 2009-07-14 | 2011-01-20 | Biogen Idec Ma Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| KR20120118088A (ko) | 2009-11-24 | 2012-10-25 | 앨더바이오 홀딩스 엘엘씨 | Ⅰｌ-6에 대한 항체 및 이들의 용도 |
| KR20220070586A (ko) | 2010-11-08 | 2022-05-31 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| WO2012071561A2 (en) | 2010-11-23 | 2012-05-31 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of anemia |
| WO2015054293A1 (en) | 2013-10-07 | 2015-04-16 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of psoriatic arthritis |
-
2008
- 2008-05-21 NZ NZ597767A patent/NZ597767A/xx unknown
- 2008-05-21 SI SI200831772A patent/SI2164514T1/sl unknown
- 2008-05-21 CA CA2688146A patent/CA2688146C/en active Active
- 2008-05-21 AU AU2008254584A patent/AU2008254584B2/en active Active
- 2008-05-21 TW TW097118660A patent/TWI561530B/zh active
- 2008-05-21 EP EP08756095.9A patent/EP2164514B1/en active Active
- 2008-05-21 JP JP2010509538A patent/JP5833823B2/ja active Active
- 2008-05-21 US US12/153,612 patent/US7935340B2/en active Active
- 2008-05-21 CA CA2993715A patent/CA2993715A1/en not_active Abandoned
- 2008-05-21 PT PT16195797T patent/PT3187506T/pt unknown
- 2008-05-21 DK DK16195797.2T patent/DK3187506T3/da active
- 2008-05-21 ES ES08756095.9T patent/ES2610607T3/es active Active
- 2008-05-21 EA EA200901533A patent/EA200901533A1/ru unknown
- 2008-05-21 SI SI200832074T patent/SI3187506T1/sl unknown
- 2008-05-21 LT LTEP16195797.2T patent/LT3187506T/lt unknown
- 2008-05-21 HU HUE16195797A patent/HUE043782T2/hu unknown
- 2008-05-21 TR TR2019/05366T patent/TR201905366T4/tr unknown
- 2008-05-21 MX MX2015001768A patent/MX349322B/es unknown
- 2008-05-21 SG SG2012061594A patent/SG183742A1/en unknown
- 2008-05-21 CN CN201510430038.7A patent/CN105001332B/zh active Active
- 2008-05-21 BR BRPI0811782-9A patent/BRPI0811782A2/pt not_active Application Discontinuation
- 2008-05-21 ES ES16195797T patent/ES2721753T3/es active Active
- 2008-05-21 DK DK08756095.9T patent/DK2164514T3/en active
- 2008-05-21 KR KR1020147029836A patent/KR101741731B1/ko active IP Right Grant
- 2008-05-21 PT PT87560959T patent/PT2164514T/pt unknown
- 2008-05-21 HU HUE08756095A patent/HUE032563T2/en unknown
- 2008-05-21 MX MX2009012492A patent/MX2009012492A/es active IP Right Grant
- 2008-05-21 US US12/601,295 patent/US20100290993A1/en not_active Abandoned
- 2008-05-21 TW TW103112322A patent/TWI617576B/zh active
- 2008-05-21 PL PL16195797T patent/PL3187506T3/pl unknown
- 2008-05-21 EP EP16195797.2A patent/EP3187506B1/en active Active
- 2008-05-21 PL PL08756095T patent/PL2164514T3/pl unknown
- 2008-05-21 KR KR1020097026636A patent/KR101615715B1/ko active IP Right Grant
- 2008-05-21 CN CN200880025053.1A patent/CN101754772B/zh active Active
- 2008-05-21 WO PCT/US2008/064432 patent/WO2008144763A2/en active Application Filing
- 2008-05-21 KR KR1020177014124A patent/KR101829776B1/ko active IP Right Grant
- 2008-05-21 LT LTEP08756095.9T patent/LT2164514T/lt unknown
- 2008-05-21 NZ NZ581596A patent/NZ581596A/en unknown
-
2009
- 2009-11-19 IL IL202238A patent/IL202238A/en active IP Right Grant
- 2009-11-20 NO NO20093387A patent/NO344119B1/no not_active IP Right Cessation
- 2009-12-09 ZA ZA2009/08770A patent/ZA200908770B/en unknown
- 2009-12-11 CO CO09141956A patent/CO6241159A2/es active IP Right Grant
-
2010
- 2010-06-10 HK HK10105754.3A patent/HK1138796A1/zh unknown
-
2014
- 2014-10-02 JP JP2014204059A patent/JP6189274B2/ja not_active Expired - Fee Related
- 2014-11-24 IL IL235877A patent/IL235877B/en active IP Right Grant
-
2015
- 2015-01-23 US US14/604,419 patent/US9771421B2/en not_active Expired - Fee Related
-
2016
- 2016-12-02 JP JP2016235068A patent/JP6412543B2/ja active Active
-
2017
- 2017-01-10 HR HRP20170038TT patent/HRP20170038T1/hr unknown
- 2017-03-10 CY CY20171100306T patent/CY1119068T1/el unknown
- 2017-09-13 US US15/703,414 patent/US10800841B2/en not_active Expired - Fee Related
-
2018
- 2018-08-07 IL IL261019A patent/IL261019B/en active IP Right Grant
- 2018-09-25 JP JP2018178782A patent/JP6703063B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-04 HR HRP20191013TT patent/HRP20191013T1/hr unknown
- 2019-06-18 CY CY20191100624T patent/CY1121779T1/el unknown
- 2019-08-15 NO NO20190984A patent/NO20190984A1/no not_active Application Discontinuation
- 2019-12-09 IL IL271270A patent/IL271270A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191013T1 (hr) | Protutijela na il-6 i njihova uporaba | |
| JP7218396B2 (ja) | 二重特異性抗体 | |
| WO2022042690A1 (zh) | Ccr8抗体及其应用 | |
| JP6548696B2 (ja) | ヒト抗ｉｌ−３３中和モノクローナル抗体 | |
| ES2779123T3 (es) | Nanobodies biespecíficos | |
| Adlere et al. | Modulators of CXCR4 and CXCR7/ACKR3 function | |
| JP7438958B2 (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| ES2816078T3 (es) | Polipéptidos modificados para armazones de anticuerpo biespecífico | |
| ES2617777T3 (es) | Producción de proteínas heteromultiméricas | |
| ES2564635T3 (es) | Anticuerpos anti-IL-6/IL-6R y métodos de uso de los mismos | |
| TW202016151A (zh) | 針對癌症治療之多特異性結合蛋白 | |
| JP2015535691A5 (hr) | ||
| JP2012529280A5 (hr) | ||
| JP2017505622A5 (hr) | ||
| JP2021507925A (ja) | Ｇｐｃｒヘテロマー阻害剤及びその用途 | |
| JP2010527615A5 (hr) | ||
| RU2008152443A (ru) | Антитела высокой аффинности к il-6-рецептору человека | |
| JP2011505792A5 (hr) | ||
| ES2955736T3 (es) | Producción de proteínas heteromultiméricas usando células de mamífero | |
| CN101796073B (zh) | 针对cxcr3的人源化抗体 | |
| JP2015508763A (ja) | ペプチドグリカン認識タンパク質１に結合する抗体 | |
| JP2023510972A (ja) | 抗ｓｔ２抗体及びその適用 | |
| CN105518025B (zh) | 人抗IFN-α抗体 | |
| Richter et al. | Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity | |
| HRP20200058T1 (hr) | Humana anti-il-32 protutijela |